Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center

References

• World Health Organization. WHO Coronavirus (COVID-19). Dashboard. https://covid19.who.int/. (accessed October, 7 2023).
   Google Scholar
• Collaboration GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):1–12. doi:10.1016/S0140-6736(20)30045-3.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. doi:10.1038/s41586-020-2521-4.
   PubMed Web of Science ®Google Scholar
• Council E-E, Group EW, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87–94. doi:10.1093/ndt/gfaa314.
   PubMed Web of Science ®Google Scholar
• Rubin D, Chan-Tack K, Farley J, et al. FDA approval of Remdesivir - A step in the right direction. N Engl J Med. 2020;383(27):2598–2600. doi:10.1056/NEJMp2032369.
   PubMed Web of Science ®Google Scholar
• Kmietowicz Z. Covid-19: selected NHS patients will be treated with remdesivir. BMJ. 2020;369:m2097. doi:10.1136/bmj.m2097.
   PubMedGoogle Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences, Inc. Remdesivir (Veklury) [package insert]. https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf. (accessed 14 Augest 2023).
   Google Scholar
• European Medicines Agency: Summary on compassionate use. Remdesivir Gilead. 2020. Available at: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead. _en. pdf. (accessed 14 August 2023).
   Google Scholar
• Stella VJ, Rajewski RA. Sulfobutylether-beta-cyclodextrin. Int J Pharm. 2020;583:119396. doi:10.1016/j.ijpharm.2020.119396.
   PubMedGoogle Scholar
• Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291–3301. doi:10.1002/jps.22109.
   PubMed Web of Science ®Google Scholar
• Davoudi-Monfared E, Ahmadi A, Karimpour-Razkenari E, et al. Remdesivir administration in COVID-19 patients with renal impairment: a systematic review. Am J Ther. 2022;29(5):e520–e33. doi:10.1097/MJT.0000000000001543.
   PubMed Web of Science ®Google Scholar
• Ackley TW, McManus D, Topal JE, et al. A valid warning or clinical lore: an evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. Antimicrob Agents Chemother. 2021;65(2):e02290-20. doi:10.1128/AAC.02290-20.
   Web of Science ®Google Scholar
• Sunny S, Samaroo-Campbell J, Abdallah M, et al. Is remdesivir safe in patients with renal impairment? Experience at a large tertiary urban medical center. Infection. 2023;51(1):247–252. doi:10.1007/s15010-022-01850-7.
   PubMed Web of Science ®Google Scholar
• Seethapathy R, Wang Q, Zhao S, et al. Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function. PLoS One. 2023;18(2):e0279765. doi:10.1371/journal.pone.0279765.
   PubMed Web of Science ®Google Scholar
• Wang S, Huynh C, Islam S, et al. Assessment of safety of remdesivir in covid - 19 patients with estimated glomerular filtration rate (eGFR) < 30 ml/min per 1.73 m;2. J Intensive Care Med. 2022;37(6):764–768. doi:10.1177/08850666211070521.
   PubMed Web of Science ®Google Scholar
• Babar ZU, Dodani SK, Nasim A, et al. Outcome of COVID-19 and tolerance of remdesivir in patients with renal failure: a single center experience from Pakistan. J Infect Dev Ctries. 2023;17(6):812–818. doi:10.3855/jidc.17136.
   PubMed Web of Science ®Google Scholar
• Stancampiano F, Jhawar N, Alsafi W, et al. Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: a retrospective multicenter study. Clin Infect Pract. 2022;16:100207.
   PubMedGoogle Scholar
• Umemura T, Mutoh Y, Mizuno T, et al. Safety evaluation of remdesivir for COVID-19 patients with eGFR < 30 mL/min without renal replacement therapy in a japanese single-center study. Healthcare (Basel). 2022;10(11):2299.
   PubMedGoogle Scholar
• Cheng M, Fowler R, Murthy S, et al. Remdesivir in patients with severe kidney dysfunction: a secondary analysis of the CATCO randomized trial. JAMA Netw Open. 2022;5(8):e2229236. doi:10.1001/jamanetworkopen.2022.29236.
   PubMed Web of Science ®Google Scholar
• Silva NAO, Zara A, Figueras A, et al. Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database. Cad Saude Publica. 2021;37(10):e00077721. doi:10.1590/0102-311X00077721.
   PubMed Web of Science ®Google Scholar
• Wu B, Luo M, Wu F, et al. Acute kidney injury associated with remdesivir: a comprehensive pharmacovigilance analysis of COVID-19 reports in FAERS. Front Pharmacol. 2022;13:692828. doi:10.3389/fphar.2022.692828.
   PubMed Web of Science ®Google Scholar
• Gerard AO, Laurain A, Fresse A, et al. Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database. Clin Pharmacol Ther. 2021;109(4):1021–1024.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Taiwan Centers for Disease Control. Guidelines for Clinical Management of Novel Coronavirus (SARS-CoV-2) Infection. May. 2022;26 https://www.cdc.gov.tw/File/Get/ZA_eJYJTL7Zy0kVG7f24Qg (accessed May 6 2024).
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461–470. doi:10.7326/0003-4819-130-6-199903160-00002.
   PubMed Web of Science ®Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84. doi:10.1159/000339789.
   PubMedGoogle Scholar
• Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2019;140(8):e382–e482. doi:10.1161/CIR.0000000000000721.
   PubMed Web of Science ®Google Scholar
• Taiwan Centers for Disease Control. Management of confirmed cases of severe specific infectious pneumonia and conditions for de-isolation treatment. April 3, 2022. https://www.cdc.gov.tw/Uploads/4a75642a-55f7-4e9f-91a7-91104aac26d0.pdf. (accessed May 6 2024).
   Google Scholar
• Taiwan Centers for Disease Control. Hospital Medical Contingency Plan for COVID-19. April 6, 2022. https://www.chshb.gov.tw/sites/default/files/2022-04/%E9%86%AB%E9%99%A2%E5%9B%A0%E6%87%89COVID-19%E9%86%AB%E7%99%82%E6%87%89%E8%AE%8A%E6%8E%AA%E6%96%BD1110406.pdf. (accessed May 6 2024).
   Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/000180580.
   PubMed Web of Science ®Google Scholar
• Rostoker G, Andrivet P, Pham I, et al. A modified Cockcroft-Gault formula taking into account the body surface area gives a more accurate estimation of the glomerular filtration rate. J Nephrol. 2007;20(5):576–585.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, et al. Acute dialysis quality initiative w. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004;8(4):R204–12. doi:10.1186/cc2872.
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi:10.1186/cc5713.
   PubMed Web of Science ®Google Scholar
• Molaei E, Molaei A, Hayes AW, et al. Remdesivir: treatment of COVID-19 in special populations. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(6):3829–3855. doi:10.1007/s00210-023-02927-2.
   PubMedGoogle Scholar
• Elec F, Magnusson J, Elec A, et al. COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome - a retrospective cohort study. Int J Infect Dis. 2022;118:247–253.
   PubMed Web of Science ®Google Scholar
• Solera JT, Árbol BG, Mittal A, et al. Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023. Am J Transplant. 2024. Published online Mar 17, 2024. doi:10.1016/j.ajt.2024.03.011.
   PubMedGoogle Scholar
• Ho CC, Wu SL, Tsai HY, et al. A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients. J Chin Med Assoc. 2023;86(5):499–505. doi:10.1097/JCMA.0000000000000910.
   PubMed Web of Science ®Google Scholar
• Chan L, Chaudhary K, Saha A, et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151–160.
   PubMed Web of Science ®Google Scholar
• Contreras-Villamizar K, Barbosa O, Munoz AC, et al. Risk factors associated with acute kidney injury in a cohort of hospitalized patients with COVID-19. BMC Nephrol. 2023;24(1):140. doi:10.1186/s12882-023-03172-8.
   PubMed Web of Science ®Google Scholar
• Zhang J, Pang Q, Zhou T, et al. Risk factors for acute kidney injury in COVID-19 patients: an updated systematic review and meta-analysis. Ren Fail. 2023;45(1):2170809.
   PubMed Web of Science ®Google Scholar
• Consortium W, WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941–1953. doi:10.1016/S0140-6736(22)00519-0.
   PubMed Web of Science ®Google Scholar
• Bistrovic P, Manola S, Lucijanic M. Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary Centre. Postgrad Med J. 2022;98(1161):501–502. doi:10.1136/postgradmedj-2021-141079.
   PubMed Web of Science ®Google Scholar
• Alsowaida YS, Shehadeh F, Kalligeros M, et al. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: a retrospective cohort study. Front Pharmacol. 2023;14:1106044. doi:10.3389/fphar.2023.1106044.
   PubMed Web of Science ®Google Scholar
• Umeh C, Giberson C, Kumar S, et al. A multicenter retrospective analysis on the etiology of bradycardia in COVID-19 patients. Cureus. 2022;14(1):e21294. doi:10.7759/cureus.21294.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Bauzon JS, Batra K, et al. Clinical characteristics and implications of bradycardia in COVID-19 patients treated with remdesivir: a single-center retrospective cohort study. Clin Drug Investig. 2022;42(9):763–774. doi:10.1007/s40261-022-01187-x.
   PubMed Web of Science ®Google Scholar
• Pantazopoulos I, Mavrovounis G, Dimeas G, et al. Remdesivir-induced bradycardia is not associated with worse outcome in patients with COVID-19: a retrospective analysis. Am J Cardiovasc Drugs. 2022;22(6):705–710. doi:10.1007/s40256-022-00547-4.
   PubMed Web of Science ®Google Scholar
• Seethapathy R, Zhao S, Long JD, et al. A propensity Score-Matched observational study of remdesivir in patients with COVID-19 and severe kidney disease. Kidney360. 2022;3(2):269–278. doi:10.34067/KID.0006152021.
   PubMedGoogle Scholar
• Ai MY, Chang WL, Yang CJ. Remdesivir-Induced bradycardia and mortality in SARS-CoV-2 infection, potential risk factors assessment: a systematic review and Meta-Analysis. J Clin Med. 2023;12(24):7518. doi:10.3390/jcm12247518.
   PubMed Web of Science ®Google Scholar
• Ishisaka Y, Aikawa T, Malik A, et al. Association of remdesivir use with bradycardia: a systematic review and meta-analysis. J Med Virol. 2023;95(8):e29018. doi:10.1002/jmv.29018.
   PubMed Web of Science ®Google Scholar
• Hajimoradi M, Sharif Kashani B, Dastan F, et al. Remdesivir associated sinus bradycardia in patients with COVID-19: a prospective longitudinal study. Front Pharmacol. 2022;13:1107198. doi:10.3389/fphar.2022.1107198.
   PubMed Web of Science ®Google Scholar